GEM05 for Patients With Multiple Myeloma Under 65 Years (GEM05MENOS65)
A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autologous Hemopoietic Stem Cell Support and Maintenance Treatment With Interferon-a Versus Thalidomide Versus Thalidomide / Velcade in Untreated Patients With Multiple Myeloma Less Than 65 Yrs Old
Sponsor: PETHEMA Foundation
Listed as NCT00461747, this PHASE3 trial focuses on Multiple Myeloma and remains completed. Sponsored by PETHEMA Foundation, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Mar 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PETHEMA Foundation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albacete, Spain , Alcorcón, Spain , Alicante, Spain , Badajoz, Spain , Badalona, Spain , Barcelona, Spain , Bilbao, Spain , Castelló, Spain , Ciudad Real, Spain , Cuenca, Spain and 40 more locations